S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission
- PMID:25721168
- DOI: 10.1159/000371890
S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission
Abstract
We have previously reported that S-777469 [1-([6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]amino)-cyclohexanecarboxylic acid], a novel cannabinoid type 2 receptor (CB2) agonist, significantly suppressed compound 48/80-induced scratching behavior in mice in a dose-dependent manner when it was administered orally. Here, we demonstrated that the inhibitory effects of S-777469 on compound 48/80-induced scratching behavior are reversed by pretreatment with SR144528, a CB2-selective antagonist. In addition, we investigated the effects of S-777469 on itch-associated scratching behavior induced by several pruritogenic agents in mice and rats. S-777469 significantly suppressed scratching behavior induced by histamine or substance P in mice or by serotonin in rats. In contrast, the H1-antihistamine fexofenadine clearly inhibited histamine-induced scratching behavior but did not affect scratching behavior induced by substance P or serotonin. Moreover, S-777469 significantly inhibited histamine-induced peripheral nerve firing in mice. In conclusion, these results suggest that S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.
© 2015 S. Karger AG, Basel
Similar articles
- Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice.Kamei J, Nagase H.Kamei J, et al.Eur J Pharmacol. 2001 Apr 20;418(1-2):141-5. doi: 10.1016/s0014-2999(01)00941-4.Eur J Pharmacol. 2001.PMID:11334876
- Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch.Akiyama T, Carstens IM, Carstens E.Akiyama T, et al.Pain. 2010 Nov;151(2):378-383. doi: 10.1016/j.pain.2010.07.024. Epub 2010 Aug 14.Pain. 2010.PMID:20709455Free PMC article.
- Scratching behavior induced by pruritogenic but not algesiogenic agents in mice.Kuraishi Y, Nagasawa T, Hayashi K, Satoh M.Kuraishi Y, et al.Eur J Pharmacol. 1995 Mar 14;275(3):229-33. doi: 10.1016/0014-2999(94)00780-b.Eur J Pharmacol. 1995.PMID:7539379
- Inhibitory effect of methanol extract of Ganoderma lucidum on acute itch-associated responses in mice.Zhang Q, Andoh T, Konno M, Lee JB, Hattori M, Kuraishi Y.Zhang Q, et al.Biol Pharm Bull. 2010;33(5):909-11. doi: 10.1248/bpb.33.909.Biol Pharm Bull. 2010.PMID:20460776
- Frontiers in pruritus research: scratching the brain for more effective itch therapy.Paus R, Schmelz M, Bíró T, Steinhoff M.Paus R, et al.J Clin Invest. 2006 May;116(5):1174-86. doi: 10.1172/JCI28553.J Clin Invest. 2006.PMID:16670758Free PMC article.Review.
Cited by
- Molecular mechanisms of pruritus in prurigo nodularis.Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, Shen Y, Tang H.Shao Y, et al.Front Immunol. 2023 Nov 23;14:1301817. doi: 10.3389/fimmu.2023.1301817. eCollection 2023.Front Immunol. 2023.PMID:38077377Free PMC article.Review.
- Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias.Sharma R, Singh S, Whiting ZM, Molitor M, Vernall AJ, Grimsey NL.Sharma R, et al.Int J Mol Sci. 2023 Mar 29;24(7):6406. doi: 10.3390/ijms24076406.Int J Mol Sci. 2023.PMID:37047385Free PMC article.
- Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.Yook HJ, Lee JH.Yook HJ, et al.Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.Int J Mol Sci. 2024.PMID:38791201Free PMC article.Review.
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.Ramer R, Hinz B.Ramer R, et al.Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102.Cells. 2022.PMID:36552866Free PMC article.Review.
- Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.Tóth KF, Ádám D, Bíró T, Oláh A.Tóth KF, et al.Molecules. 2019 Mar 6;24(5):918. doi: 10.3390/molecules24050918.Molecules. 2019.PMID:30845666Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials